SITC Immune Effector Cell-related Adverse Events Guideline

SITC's Cancer Immunotherapy Guidelines program is a collection of clinical practice guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure recommendations are unbiased, transparent, and balanced. 

This guidelines addresses some of the most commonly reported toxicities during treatment with FDA-approved CAR T cell therapies as well as other emerging IEC therapies, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and persistent cytopenias and resultant infections, among other key considerations for oncologists treating their patients with these agents.

A companion guideline on the management of immune checkpoint inhibitor-related adverse events published on June 25, 2021 in the Journal for ImmunoTherapy of Cancer (JITC).

Published Guideline 

READ GUIDELINE

"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events" originally published in Journal for Immunotherapy of Cancer (JITC) on December 16, 2020 and has since been updated.

SITC continuously evaluates the field for practice-changing data and new FDA approvals. The Immune Checkpoint Inhibitor-related Adverse Events Guideline Expert Panel guides the development of updates within this CPG. Updates appear in the SITC CPG Mobile App and as annotated text accompanying the original publication in JITC.

Highlights of Updated Content: 

• IEC CRS Management Algorithm
• IEC ICANS Management Algorithm
• IEC Cardiotoxicity Anticoagulant Management Algorithm  

SITC is a proponent of collaboration and harmonization of efforts between like-minded organizations whenever possible. SITC wishes to thank the American Society of Hematology (ASH), the American Society for Transplantation and Cellular Therapy (ASTCT) and the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center for providing representatives to serve on SITC’s Immune Effector Cell-related Adverse Events Expert Panel to aid in the development of this clinical practice guideline.